Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Short-term Investments (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Short-term Investments for 9 consecutive years, with $334.6 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 44.6% to $334.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $334.6 million through Dec 2025, up 44.6% year-over-year, with the annual reading at $334.6 million for FY2025, 44.6% up from the prior year.
  • Short-term Investments for Q4 2025 was $334.6 million at Rhythm Pharmaceuticals, down from $364.0 million in the prior quarter.
  • The five-year high for Short-term Investments was $364.0 million in Q3 2025, with the low at $122.4 million in Q2 2022.
  • Average Short-term Investments over 5 years is $218.2 million, with a median of $212.1 million recorded in 2023.
  • The sharpest move saw Short-term Investments crashed 59.04% in 2022, then surged 45.09% in 2025.
  • Over 5 years, Short-term Investments stood at $235.6 million in 2021, then decreased by 12.73% to $205.6 million in 2022, then grew by 4.94% to $215.8 million in 2023, then increased by 7.26% to $231.4 million in 2024, then skyrocketed by 44.6% to $334.6 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $334.6 million, $364.0 million, and $155.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.